Orexigen Therapeutics Inc. (OREX) Sets New 1-Year Low at $3.42
Orexigen Therapeutics Inc. (NASDAQ:OREX) shares hit a new 52-week low during trading on Monday . The company traded as low as $3.42 and last traded at $3.42, with a volume of 150,675 shares changing hands. The stock had previously closed at $3.51.
Separately, Zacks Investment Research raised Orexigen Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, July 11th. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. The stock has an average rating of “Hold” and a consensus target price of $2.61.
The firm’s market capitalization is $49.93 million. The firm has a 50 day moving average of $4.37 and a 200 day moving average of $8.09.
Orexigen Therapeutics (NASDAQ:OREX) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. The business had revenue of $5 million for the quarter, compared to the consensus estimate of $7.78 million. During the same period in the previous year, the company earned ($0.14) EPS. The company’s revenue for the quarter was up 16.3% on a year-over-year basis. Analysts predict that Orexigen Therapeutics Inc. will post ($5.61) earnings per share for the current year.
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.